Results 151 to 160 of about 6,511 (194)

Idiopathic hyperprolactinemia-associated hypogonadism in men presenting with normal testosterone levels. [PDF]

PLoS One
Cheng X, Xiao Y, Deng Y, Chen Q, Wen X, Zhou E, Zhou H.   +6 more
europepmc   +1 more source

Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes. [PDF]

Pituitary
Mamelak AN, Fox R, Rosenberg Y, Gomez D, Cui Y, Shlomo AB, Labadzhyan A, Liu NA, Bonert V, Cooper O.   +9 more
europepmc   +1 more source

Adenoma receptors and histologic characteristics determining management outcomes.

J Clin Endocrinol Metab
Wildemberg LE, Gadelha MR.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cabergoline in acromegaly

Pituitary, 2016
Acromegaly, a rare disease due to growth hormone (GH) hypersecretion by a pituitary adenoma, is associated with severe comorbidity and premature death if not adequately treated. The usual first-line treatment is surgery. Various drugs, including somatostatin receptor ligands, dopamine agonists and GH receptor antagonists, are now available for use if ...
Emmanuelle Kuhn, Philippe Chanson, Kuhn Emmanuelle   +2 more
exaly   +3 more sources

Cabergoline

Expert Opinion on Pharmacotherapy, 2000
Cabergoline (CAB) (1-[(6-allelylergolin-8 beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethyl-urea) is an ergoline derivative with potent, selective and long-lasting inhibitory activity on prolactin (PRL) secretion acting on dopamine receptors present in pituitary lactotrophes.
COLAO, ANNAMARIA, LOMBARDI, GAETANO, ANNUNZIATO, LUCIO   +2 more
openaire   +3 more sources